Humacyte intends to use the net proceeds that it will receive from the offering to fund the commercialization of SYMVESS™ in the vascular trauma indication, the development of the product candidates ...

Humacyte intends to use the net proceeds that it will receive from the offering to fund the commercialization of SYMVESS™ in the vascular trauma indication, the development of the product candidates ...

DURHAM, N.C., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable ...

Humacyte's stock struggles despite FDA approval for Symvess, with financial concerns and slow adoption impacting future ...

DURHAM, N.C., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at ...

Feb. 4, 2025 — Research has shown that a potential new targeted therapy for childhood brain cancer is effective in infiltrating and killing tumor cells in ... Feb. 4, 2025 — Researchers have ...

People fully vaccinated against hepatitis B who are not immunocompromised can expect sustained immunity throughout their ...

Objective: The study aimed to investigate the efficacy and safety of acellular porcine corneal stroma (APCS) for lamellar keratoplasty in the treatment of corneal ulcers. Methods: A total of 14 ...

North Carolina's life sciences ecosystem is thriving, thanks in no small part to the leadership and innovation of women ...

February 26, 2025—Humacyte, Inc. announced the commercial launch of Symvess, an acellular tissue engineered vessel-tyod (ATEV) indicated for use in adults as a vascular conduit for extremity arterial ...